Works in Cancer Chemotherapy & Pharmacology, 2023, Vol 91, Issue 6

Results: 8

Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 457, doi. 10.1007/s00280-023-04530-x

By:

Patel, Ankit;
Bhatt, Niraj;
Prakash, S. S.;
Biswas, Ghanashyam;
Nagarkar, Rajnish;
Roy, Bodhisatta;
Samal, Priyanka;
Agrawal, Narendra;
Meshram, Sushil;
Kaushal, Ashish;
Satheesh, C. T.;
Wategaonkar, Ravikumar;
Thiagarajan, Kasi Viswanathan;
Jain, Kartikeya;
Vijayaveeran, P.;
Mukherjee, Kalyan;
Singh, Kishore;
Patil, Tushar;
Jain, Amit;
Dolai, Tuphan Kanti

Publication type:

Article

Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 507, doi. 10.1007/s00280-023-04538-3

By:

Korver, Samantha K.;
Bowen, Joanne M.;
Gibson, Rachel J.;
Ball, Imogen A.;
Secombe, Kate R.;
Wain, Taylor J.;
Logan, Richard M.;
Tuke, Jonathan;
Mead, Kelly R.;
Richards, Alison M.;
Karapetis, Christos S.;
Keefe, Dorothy M.;
Coller, Janet K.

Publication type:

Article

Associations of plasma aprepitant and its N-dealkylated metabolite with cachexia status and clinical responses in head and neck cancer patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 481, doi. 10.1007/s00280-023-04537-4

By:

Suzuki, Yusuke;
Naito, Takafumi;
Shibata, Kaito;
Hosokawa, Seiji;
Kawakami, Junichi

Publication type:

Article

Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 523, doi. 10.1007/s00280-023-04536-5

By:

Hu, Chaoying;
Zhang, Yanping;
Pei, Tong;
Liu, Ping;
Zhang, Lan

Publication type:

Article

The prevalence of end-of-life chemotherapy and targeted therapy in Japan, assessed using a health claims database.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 501, doi. 10.1007/s00280-023-04535-6

By:

Tsuchiya, Masami;
Obara, Taku;
Kikuchi, Masafumi;
Mano, Nariyasu

Publication type:

Article

Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 491, doi. 10.1007/s00280-023-04534-7

By:

Jang, Seong;
Strickland, Bill;
Finis, Lynda;
Kooijman, Jeffrey J.;
Melis, Janneke J. T. M.;
Zaman, Guido J. R.;
Van Tornout, Jan

Publication type:

Article

Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 447, doi. 10.1007/s00280-023-04517-8

By:

Groenland, Stefanie L.;
Janssen, J. M.;
Nijenhuis, C. M.;
de Vries, N.;
Rosing, H.;
Wilgenhof, S.;
van Thienen, J. V.;
Haanen, J. B. A. G.;
Blank, C. U.;
Beijnen, J. H.;
Huitema, A. D. R.;
Steeghs, N.

Publication type:

Article

Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 469, doi. 10.1007/s00280-023-04527-6

By:

Yamamoto, Noboru;
Koyama, Takafumi;
Shimizu, Toshio;
Todaka, Akiko;
Kawakami, Takeshi;
Erzen, Damijan;
Sarashina, Akiko;
Li, Bin;
Hou, Jianrui;
Yamazaki, Kentaro

Publication type:

Article